Brief: Alligator And Orion Develop Option Under 2021 Collaboration And License Agreement
April 26 (Reuters) - Alligator Bioscience ATORX.ST :
* ALLIGATOR BIOSCIENCE AND ORION CORPORATION ANNOUNCE
EXERCISE OF
DEVELOPMENT OPTION UNDER 2021 IMMUNO-ONCOLOGY RESEARCH
COLLABORATION AND LICENSE AGREEMENT
* ALLIGATOR BIOSCIENCE AB - EXERCISE OF THIS DEVELOPMENT
OPTION
TRIGGERS AN UNDISCLOSED MILESTONE PAYMENT TO ALLIGATOR
Source text for Eikon: ID:nMFN8MFN2D
Further company coverage: ATORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Alligator Bioscience AB
See all newsSweden's Alligator Bioscience Q3 sales fall as R&D winds down
Brief: Alligator Bioscience Q3 EBIT SEK -19.3 Million
Brief: Alligator Bioscience Appoints Johan Gileus As CEO
Brief: Alligator Bioscience Announces Final Outcome In Rights Issue
Brief: Alligator Bioscience To Initially Receive SEK 58.8 Mln From Rights Issue